Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Brazil stem cell research & development plan drives embryo register:

This article was originally published in Clinica

Executive Summary

Brazil is consulting on the creation and operation of a national human embryo register that will form the basis for the co-ordination and surveillance of therapeutic and research uses of all embryonic tissue. The plans proposed by healthcare regulatory agency Anvisa are that SisEmbrio be used to register all embryos surplus to IVF treatment and information on the tissues derived from them, including stem cells, for a period of 20 years. The handling of the embryos and the management and submission of their data to SisEmbrio will be the responsibility of the BCTG network of cell and regenerative tissue banks. The register will automatically generate a unique code for each embryo and record data on their subsequent use. Anvisa will be responsible for SisEmbrio. The 30-day consultation ends August 26.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT052541

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel